Howard Horn's most recent trade in Ultragenyx Pharmaceutical Inc. was a trade of 3,061 Common Stock done at an average price of $23.6 . Disclosure was reported to the exchange on Feb. 2, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc | Howard Horn | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.56 per share. | 02 Feb 2026 | 3,061 | 88,935 (0%) | 0% | 23.6 | 72,117 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Howard Horn | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.84 per share. | 02 Jan 2026 | 3,150 | 91,996 (0%) | 0% | 22.8 | 71,946 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Howard Horn | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.38 per share. | 10 Dec 2025 | 3,081 | 95,146 (0%) | 0% | 36.4 | 112,087 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Howard Horn | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.51 per share. | 13 Oct 2025 | 7,942 | 98,227 (0%) | 0% | 31.5 | 250,252 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Howard Horn | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 40.40 per share. | 06 Mar 2025 | 1,785 | 106,169 (0%) | 0% | 40.4 | 72,114 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Howard Horn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 28,160 | 28,160 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical Inc | Howard Horn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 15,653 | 107,954 (0%) | 0% | 0 | Common Stock | |
| Ultragenyx Pharmaceutical Inc | Howard Horn | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 52.76 per share. | 10 Oct 2024 | 7,465 | 92,301 (0%) | 0% | 52.8 | 393,853 | Common Stock |
| Ultragenyx Pharmaceutical Inc | Howard Horn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 34,200 | 34,200 | - | - | Stock Option (Right to Buy) | |
| Ultragenyx Pharmaceutical Inc | Howard Horn | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 19,400 | 99,766 (0%) | 0% | 0 | Common Stock | |
| Vir biotech Inc | Howard Horn | CFO | Sale of securities on an exchange or to another person at price $ 25.97 per share. | 23 Feb 2023 | 2,248 | 230,712 (0%) | 0% | 26.0 | 58,387 | Common Stock |
| Vir biotech Inc | Howard Horn | CFO | Sale of securities on an exchange or to another person at price $ 25.29 per share. | 17 Feb 2023 | 2,424 | 232,960 (0%) | 0% | 25.3 | 61,298 | Common Stock |
| Vir biotech Inc | Howard Horn | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Vir biotech Inc | Howard Horn | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 35,000 | 235,384 (0%) | 0% | 0 | Common Stock | |
| Vir biotech Inc | Howard Horn | CFO | Sale of securities on an exchange or to another person at price $ 31.93 per share. | 17 Feb 2022 | 2,393 | 200,384 (0%) | 0% | 31.9 | 76,411 | Common Stock |
| Vir biotech Inc | Howard Horn | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Vir biotech Inc | Howard Horn | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 25,000 | 202,777 (0%) | 0% | 0 | Common Stock |